Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

[Technological approaches to development of whole-virion inactivated vaccine from recombinant strain against A/H5N1 influenza in the Republic of Kazakhstan].

Kydyrbaev ZhK, Mamadaliev SM, Asanzhanova NN, Tabynov KK, Ryskel'dinova ShZh, Cherviakova OV, Sandybaev NT, Khaĭrullin BM, Kiselev OI.

Zh Mikrobiol Epidemiol Immunobiol. 2012 Sep-Oct;(5):54-9. Russian.

PMID:
23163037
[PubMed - indexed for MEDLINE]
2.
3.

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.

Clin Vaccine Immunol. 2013 Aug;20(8):1314-9. doi: 10.1128/CVI.00096-13. Epub 2013 Jun 26.

PMID:
23803900
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.

Miyaki C, Quintilio W, Miyaji EN, Botosso VF, Kubrusly FS, Santos FL, Iourtov D, Higashi HG, Raw I.

Vaccine. 2010 Mar 16;28(13):2505-9. doi: 10.1016/j.vaccine.2010.01.044. Epub 2010 Jan 30.

PMID:
20123051
[PubMed - indexed for MEDLINE]
5.

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W.

Lancet. 2006 Sep 16;368(9540):991-7.

PMID:
16980114
[PubMed - indexed for MEDLINE]
6.

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.

Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A.

PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898. Epub 2012 Jan 27.

PMID:
22303469
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

PMID:
18786689
[PubMed - indexed for MEDLINE]
Free Article
8.

Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.

Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.

Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10.

PMID:
21911027
[PubMed - indexed for MEDLINE]
9.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

PMID:
19281330
[PubMed - indexed for MEDLINE]
Free Article
10.

A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].

Plosker GL.

Drugs. 2012 Jul 30;72(11):1543-57. doi: 10.2165/11209650-000000000-00000. Review.

PMID:
22788239
[PubMed - indexed for MEDLINE]
11.

Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.

Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, Kawaoka Y, Takeuchi Y, Kida H, Ogasawara K.

Immunology. 2008 Jun;124(2):155-65. doi: 10.1111/j.1365-2567.2007.02745.x. Epub 2008 Jan 16.

PMID:
18205793
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection.

Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K, Tochihara S, Itamura S, Odagiri T, Tashiro M, Okada K, Miyazaki C, Ueda K.

Microbiol Immunol. 2010 Feb;54(2):81-8. doi: 10.1111/j.1348-0421.2009.00191.x. Erratum in: Microbiol Immunol. 2011 Nov;55(11):822. Dosage error in article text.

PMID:
20377741
[PubMed - indexed for MEDLINE]
13.

[Comparative clinical trial of vaccines against avian influenza].

Zverev VV, Katlinskiĭ AV, Kostinov MP, Zhirova SN, Erofeeva MK, Stukova MA, Korovkin SA, Mel'nikov SIa, Semchenko AV, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6. Russian.

PMID:
17672124
[PubMed - indexed for MEDLINE]
14.

Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine.

Geeraedts F, ter Veer W, Wilschut J, Huckriede A, de Haan A.

Vaccine. 2012 Oct 5;30(45):6501-7. doi: 10.1016/j.vaccine.2012.07.036. Epub 2012 Jul 27.

PMID:
22841974
[PubMed - indexed for MEDLINE]
15.

Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.

Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ.

Vaccine. 2010 Aug 31;28(38):6221-7. doi: 10.1016/j.vaccine.2010.07.008. Epub 2010 Jul 16.

PMID:
20638454
[PubMed - indexed for MEDLINE]
16.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
[PubMed - indexed for MEDLINE]
17.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.

Vaccine. 2008 Nov 25;26(50):6383-91. doi: 10.1016/j.vaccine.2008.08.046. Epub 2008 Sep 16.

PMID:
18801398
[PubMed - indexed for MEDLINE]
18.

Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.

Heldens JG, Glansbeek HL, Hilgers LA, Haenen B, Stittelaar KJ, Osterhaus AD, van den Bosch JF.

Vaccine. 2010 Nov 29;28(51):8125-31. doi: 10.1016/j.vaccine.2010.09.097. Epub 2010 Oct 13.

PMID:
20950729
[PubMed - indexed for MEDLINE]
19.

Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement.

Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD.

J Virol. 2008 Mar;82(5):2565-9. Epub 2007 Dec 19.

PMID:
18094159
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Characterization of a whole, inactivated influenza (H5N1) vaccine.

Tada Y.

Influenza Other Respir Viruses. 2008 Nov;2(6):261-6. doi: 10.1111/j.1750-2659.2008.00066.x.

PMID:
19453403
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk